Myasthene Syndrome

Jörn Peter Sieb

doi:10.1055/a-0941-6925

Neurologie up2date, Table of Contents

Neurologie up2date 2019; 2(04): 415-434
DOI: 10.1055/a-0941-6925

Myopathien und Neuropathien

Georg Thieme Verlag KG Stuttgart · New York

Myasthene Syndrome

Myasthenia gravis, Lambert-Eaton-myasthenisches Syndrom und kongenitale Myastheniesyndrome

Authors

Jörn Peter Sieb

Abstract

All articles of this category

Störungen der neuromuskulären Transmission sind selten, jedoch gibt es sehr wirksame Therapieoptionen. Außer den unterschiedlichen Formen der Myasthenia gravis (MG) werden hier Diagnose und Therapie des ebenfalls autoimmun bedingten Lambert-Eaton-myasthenischen Syndroms (LEMS) und der kongenitalen Myastheniesyndrome dargestellt.

Schlüsselwörter

Muskelschwäche - neuromuskuläre Signalübertragung - Myasthenia gravis - Lambert-Eaton-myasthenisches Syndrom

Full Text

References

Literatur
1 Gilhus NE, Skeie GO, Romi F. et al. Myasthenia gravis – autoantibody characteristics and their implications for therapy. Nat Rev Neurol 2016; 12: 259-268 doi:10.1038/nrneurol.2016.44
2 Sieb JP. Myasthenia gravis: an update for the clinician. Clin Exp Immunol 2014; 175: 408-418 doi:10.1111/cei.12217
3 Gilhus NE, Tzartos S, Evoli A. et al. Myasthenia gravis. Nat Rev Dis Primers 2019; 5: 30 doi:10.1038/s41572-019-0079-y
4 Köhler W, Sieb JP. Myasthenia gravis. 4. Aufl.. Bremen: UNI-MED; 2012. (5. Auflage in Vorbereitung)
5 Sieb JP. Monoklonale Antikörper bei Myasthenia gravis. DGNeurologie 2019; 2: 345-351
6 Morren J, Li Y. Myasthenia gravis with muscle-specific tyrosine kinase antibodies: A narrative review. Muscle Nerve 2018; 58: 344-358 doi:10.1002/mus.26107
7 Pevzner A, Schoser B, Peters K. et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol 2012; 259: 427-435 doi:10.1007/s00415-011-6194-7
8 Zhang B, Tzartos JS, Belimezi M. et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 2012; 69: 445-451 doi:10.1001/archneurol.2011.2393
9 Wolfe GI, Kaminski HJ, Aban IB. et al. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med 2016; 375: 511-522 doi:10.1056/NEJMoa1602489
10 Benatar M, Mcdermott MP, Sanders DB. et al. Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): A randomized, controlled trial. Muscle Nerve 2016; 53: 363-369 doi:10.1002/mus.24769
11 Pasnoor M, He J, Herbelin L. et al. A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis. Neurology 2016; 87: 57-64 doi:10.1212/WNL.0000000000002795
12 Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord 2018; 11: 1756285617749134 doi:10.1177/1756285617749134
13 Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol 2011; 10: 1098-1107 doi:10.1016/S1474-4422(11)70245-9
14 Maddison P, Gozzard P, Grainge MJ. et al. Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology 2017; 88: 1334-1339 doi:10.1212/WNL.0000000000003794
15 Sieb JP. Neuromuskuläre Übertragungsstörungen. In: Bischoff C, Buchner H. Hrsg. SOP in der klinischen Neurophysiologie. Stuttgart: Thieme; 2017
16 Di Lorenzo R, Mente K, Li J. et al. Low specificity of voltage-gated calcium channel antibodies in Lambert-Eaton myasthenic syndrome: a call for caution. J Neurol 2018; 265: 2114-2119 doi:10.1007/s00415-018-8959-8
17 Titulaer MJ, Wirtz PW, Willems LN. et al. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol 2008; 26: 4276-4281 doi:10.1200/JCO.2008.17.5133
18 Maddison P, Titulaer MJ, Verschuuren JJ. et al. The utility of anti-SOX2 antibodies for cancer prediction in patients with paraneoplastic neurological disorders. J Neuroimmunol 2019; 326: 14-18 doi:10.1016/j.jneuroim.2018.11.003
19 Sanders DB, Juel VC, Harati Y. et al. 3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia. Muscle Nerve 2018; 57: 561-568 doi:10.1002/mus.26052
20 Engel AG. Genetic basis and phenotypic features of congenital myasthenic syndromes. Handb Clin Neurol 2018; 148: 565-589 doi:10.1016/B978-0-444-64076-5.00037-5
21 Lee M, Beeson D, Palace J. Therapeutic strategies for congenital myasthenic syndromes. Ann N Y Acad Sci 2018; 1412: 129-136 doi:10.1111/nyas.13538
22 Sieb JP. Diagnose eines kongenitalen Myasthenie-Syndroms durch eine Rapsyn-Defizienz im Erwachsenenalter. Klin Neurophysiol 2018; 49: 113-115 doi:10.1055/a-0591-0670